Wave Life Sciences reports Q2 2026 results, advances obesity and AATD pipelines
Wave began dosing in a higher-BMI cohort of its INLIGHT obesity trial and secured an FDA meeting on accelerated approval for its AATD candidate WVE-006.
SEC filing
Latest
2 stories